semaglutide pain at injection site Injecting Semaglutide: A Guide to Sites and Technique Semaglutide Injection Site Reaction

GLP-1 (glucagon-like peptide-1) plays a central role in regulating hunger signals, insulin response, and blood sugar balance

Scoliosis or Spinal Abnormalities Scoliosis is a condition where the spine curves abnormally

A randomized, controlled trial involving nearly 2,000 adults with overweight or obesity but without diabetes was conducted

A randomized, placebo-controlled Phase 2 trial (NCT02453711) of once-daily subcutaneous semaglutide (0.05, 0.1, 0.2, 0.3, or 0.4 mg following 4-weekly escalations) in subjects with obesity without T2D, showed mean weight losses of -6.0% (0.05 mg) to -13.8% (0.4 mg) with semaglutide vs -2.3% with placebo at week 52